title: Hematopoietic cytokine-dependent differentiation to eosinophils and neutrophils in a newly established acute promyelocytic leukemia cell line with t(15;17).
abstract: We recently established an acute promyelocytic leukemia (APL) cell line (HT93) that has the capacity to differentiate into neutrophils and eosinophils in response to all-trans retinoic acid (ATRA) and human hematopoietic cytokines. The cells had a myeloblastic morphology, were positive for surface CD33, CD34, and CD56, and showed the following karyotypes: 46, XY, t(1;12)(q25;p13), 2q+, t(4;6)(q12;q13), and t(15;17)(q22;q11). When the cells were cultured with ATRA, they showed nuclear segmentation and developed secondary granules consisting in part of neutrophils and eosinophils. In the presence of ATRA and granulocyte colony-stimulating factor (G-CSF), the cells showed polymorphonuclear neutrophil differentiation accompanied by expression of surface CD11b, CD15, CD10, positive activity for neutrophil alkaline phosphatase (NAP), and NAP mRNA expression. In cultures with ATRA and granulocyte-macrophage colony-stimulating factor (GM-CSF), IL (interleukin)-3, or IL-5, HT93 showed remarkable eosinophil maturation at day 8 as determined by luxol fast blue staining, in addition to expression of eosinophil peroxidase and major basic protein. These results indicate that HT93 is an APL cell line with the ability to differentiate into neutrophils and eosinophils, and that these lineages are dependent on the CSF added. HT 93 should prove to be a useful model in analyzing the effects of hematopoietic cytokines on proliferation, differentiation, and maturation of hematopoietic progenitors.
authors.affiliation: First Department of Internal Medicine, Niigata University School of Medicine, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Kishi
authors.forename: K
authors.initials: K
authors.lastname: Toba
authors.forename: T
authors.initials: T
authors.lastname: Azegami
authors.forename: N
authors.initials: N
authors.lastname: Tsukada
authors.forename: Y
authors.initials: Y
authors.lastname: Uesugi
authors.forename: M
authors.initials: M
authors.lastname: Masuko
authors.forename: H
authors.initials: H
authors.lastname: Niwano
authors.forename: S
authors.initials: S
authors.lastname: Hashimoto
authors.forename: M
authors.initials: M
authors.lastname: Sakaue
authors.forename: T
authors.initials: T
authors.lastname: Furukawa
authors.forename: T
authors.initials: T
authors.lastname: Koike
authors.forename: H
authors.initials: H
authors.lastname: Takahashi
authors.forename: T
authors.initials: T
authors.lastname: Maekawa
authors.forename: T
authors.initials: T
authors.lastname: Abe
authors.forename: Y
authors.initials: Y
authors.lastname: Aizawa
mesh_terms: D000469:Alkaline Phosphatase / Q000096:biosynthesis; D015703:Antigens, CD / Q000032:analysis; D015415:Biomarkers; D002454:Cell Differentiation / Q000187:drug effects*; D002884:Chromosomes, Human, Pair 15; D002886:Chromosomes, Human, Pair 17; D004804:Eosinophils / Q000166:cytology* / Q000187:drug effects; D004921:Erythropoietin / Q000096:biosynthesis; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology*; D006801:Humans; D007377:Interleukin-3 / Q000494:pharmacology; D015848:Interleukin-5 / Q000494:pharmacology; D007621:Karyotyping; D015473:Leukemia, Promyelocytic, Acute / Q000473:pathology*; D009504:Neutrophils / Q000166:cytology* / Q000187:drug effects; D009195:Peroxidase / Q000096:biosynthesis; D016133:Polymerase Chain Reaction; D011994:Recombinant Proteins / Q000494:pharmacology; D014178:Translocation, Genetic; D014212:Tretinoin / Q000494:pharmacology; D014407:Tumor Cells, Cultured
chemical_list: D015703:Antigens, CD; D015415:Biomarkers; D007377:Interleukin-3; D015848:Interleukin-5; D011994:Recombinant Proteins; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D014212:Tretinoin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D009195:Peroxidase; D000469:Alkaline Phosphatase